Year: 2022

Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that MAT2203 achieves impressive in vivo efficacy and has in vitro killing activity 5 to 10-fold higher than liposomal amphotericin B against two clinical isolates of pulmonary mucormycosis BEDMINSTER, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced three upcoming oral data presentations during IDWeek 2022, the premier U.S. meeting of leaders in the field of infectious diseases taking place in-person...

RALEIGH, N.C., Oct. 12, 2022 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE:MLM) (“Martin Marietta” or the “Company”) will host its third-quarter 2022 earnings conference call on Wednesday, November 2, 2022 at 11:00 a.m. Eastern Time. The Company will release results for the quarter ended September 30, 2022, that morning before the market opens. A live, listen-only webcast and supplemental information will be accessible on the Investors section of the Company’s website at www.martinmarietta.com. The conference call may also be accessed by registering here: https://register.vevent.com/register/BI38e873a0336948ef86b287a7fe390693. Please register at least 15 minutes in advance to ensure a timely connection to the call. An on-demand replay will be available on the Company’s website approximately two hours following the conclusion...

Not for distribution to U.S. newswire services or for dissemination in the United States TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) (“Giyani” or the “Company”), developer of the K.Hill battery-grade manganese project in Botswana (“K.Hill Battery Manganese Project” or “K.Hill”), announces that Jonathan Henry has been appointed Executive Chair. Mr. Henry, previously Non-Executive Chair, will manage a leadership transition period as the Company moves into the next phase of development and towards production. As part of this transition Robin Birchall has resigned as Chief Executive Officer and a director of Giyani with immediate effect. With the move of the Chair of the Board to an executive position, the Board has appointed Stephanie Hart, an existing Non-Executive Director, to the position...

– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase – Initial recommended phase two dose set at 1500 mg with dose expansion ongoing – Poster presentation with additional data at ENA available on October 26 at 9am CET/3am ET, and presented on October 28, 2022, 10:00-15:00 CET – Investor call to discuss a MCLA-129 program update on October 26 at 13:30 CET/7:30am ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody...

Record Betting Handle and Revenue Driven by Esports Betting, Growth in Casino Experiences, and Leading Brand Position Among Next Generation ConsumersRecord betting handle1 of $70.3 million in Q3 2022, up 203% year-over-year, and 83% quarter-over-quarter. Record revenue of $7.1 million in Q3 20222, up 93% year-over-year, and 35% quarter-over-quarter. With 82% of active users at Rivalry under the age of 30-years old, the Company continues to extend its brand leadership position as the betting destination for the next generation. Management to provide further details on growth strategy and opportunities at first-ever Virtual Investor Day.TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), an internationally regulated sports betting and media company, today...

Novel collaboration structure supports pipeline innovation NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. “We are excited to collaborate with Merck,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “This creative agreement is a great example of how Royalty Pharma provides innovative, win-win funding solutions and supports exciting medicines like MK-8189 across the biopharma industry. Royalty Pharma sees an exciting future opportunity to partner with Merck and other global pharmaceutical companies...

Toronto, Ontario and Cambridge, MA, Oct. 12, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement of 1,383,755 Units of the Company at a price of US$5.40 per Unit for gross proceeds of US$7,472,277.   Each Unit is comprised of one Common Share of the Company and one quarter of one Common Share purchase Warrant. Each full Warrant is exercisable for one Common Share at US$7.50 for a period of five years commencing six months from the closing of the Offering. The...

GREENWICH, Conn. , Oct. 12, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (“XPO” or the “company”) (NYSE: XPO) announced that RXO, Inc. (“RXO”), a wholly owned subsidiary of XPO, has priced an offering of $355 million of notes due 2027 (the “notes”). The notes will be issued by XPO’s wholly owned subsidiary, XPO Escrow Sub, LLC, which will, substantially concurrently with or prior to the consummation of the spin-off of RXO into a separate publicly traded company, merge with and into RXO, as a result of which the notes will become the direct obligations of RXO. The closing of the offering of the notes is expected to occur on or about October 25, 2022, subject to customary closing conditions. The notes will bear interest at a rate of 7.500% per annum payable semiannually in cash in arrears on May 15 and November 15 of each year, beginning...

The Cellebrite Guardian solution provides additional features to address the challenges around the ethical treatment of digital evidence, especially child sexual abuse material PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 12, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the release of the next generation of Cellebrite Guardian, which provides critical features aiding law enforcement in handling digital evidence in an ethical way, including storing, managing, and sharing evidence, with unmatched instant review of digital evidence. Cellebrite Guardian is an immediately deployable and highly secure SaaS-based solution that streamlines management of investigations and evidence, removes silos, and connects all...

AGOURA HILLS, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), through its wholly owned subsidiary Oncotelic Inc., a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID, today announced the approval of a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for the development of OT-101 under a project named OT-101 – a transforming growth factor-beta (TGF-β) therapeutics against long-term effects of respiratory distress post COVID-19. The scope of the project supported by BARDA includes collecting the long-term clinical data on...